Amerikanska konkurrensmyndigheten har slutfört granskningen av Pfizers förvärv av Pharmacia

Amerikanska konkurrensmyndigheten har slutfört granskningen av Pfizers förvärv av Pharmacia NEW YORK, 25 mars - Pfizer Inc och Pharmacia Corp rapporterade idag att handläggarna hos den amerikanska konkurrensmyndigheten Federal Trade Commission (FTC) slutfört granskningen av Pfizers planer för förvärvet av Pharmacia. Ett förslag till godkännande av affären, formulerat av företagen och FTC:s handläggare, läggs fram till kommissionen för godkännande och offentliggörande. Utifrån tidigare erfarenheter av FTC:s arbete beräknar Pfizer fortfarande att denna process kommer att innebära att affären genomförs i april. Mediakontakter Anne-Lie Öberg, Director Information Public Relations, Pfizer AB: 08-519 06 337, alt. 0708-506 337 Marianne Bäärnhielm, informationsdirektör Pharmacia: 08-695 72 82, alt. 070-319 50 60 För ytterligare information om Pfizer och Pharmacia, besök bolagens hemsidor: www.pfizer.se, www.pharmacia.se. Pfizer Inc utvecklar, tillverkar och marknadsför ledande receptförskrivna läkemedel för människor och djur, liksom många av världens mest välkända konsumentvarumärken. Pharmacia är ett av världens tio största läkemedelsföretag vars innovativa läkemedel och andra produkter räddar liv och förbättrar människors hälsa och välbefinnande. De 43.000 anställda i Pharmacia arbetar tillsammans med många andra intressenter för att öka livskvaliteten för människor runt om i världen och för att skapa lösningar för framtidens hälso- och sjukvård. Den 15 juli 2002 tillkännagav Pharmacia och Pfizer Inc. (NYSE: PFE) att de ingått ett definitivt avtal som innebär att Pfizer förvärvar Pharmacia genom en aktiebytestransaktion, som förväntas vara avslutad under april 2003. # # # # # DISCLOSURE NOTICE: The information contained in this document is as of March 25, 2003. The Company assumes no obligation to update any forward- looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking information about the Company's financial results and estimates, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan" "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Among the factors that could cause actual results to differ materially are the following: the success of research and development activities and the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; competitive developments affecting our current growth products; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; trade buying patterns; ability to meet generic and branded competition after the loss of patent protection for our products; trends toward managed care and health care cost containment; possible U.S. legislation affecting, among other things, pharmaceutical pricing and reimbursement, including Medicaid and Medicare; legislation or regulations in markets outside the U.S. affecting product pricing, reimbursement or access; contingencies related to actual or alleged environmental contamination; legal defense costs, insurance expense, settlement costs and the risk of an adverse decision related to product liability, patent protection and other lawsuits; the Company's ability to protect its patents and other intellectual property both domestically and internationally; interest rate and foreign currency exchange rate fluctuations; governmental laws and regulations affecting domestic and foreign operations, including tax obligations; changes in generally accepted accounting principles; any changes in business, political and economic conditions due to the threat of future terrorist activity in the U. S. and other parts of the world, and related U. S. military action overseas; ability to divest and the timing of the divestitures of the discontinued businesses; growth in costs and expenses; changes in our product mix; and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to obtain the anticipated results and synergies from our announced proposed acquisition of Pharmacia and the increased uncertainty created by the integration of the two businesses, as well as our proposed sale of the Adams and Schick-Wilkinson Sword businesses and of the women's health product lines. A further list and description of these risks, uncertainties and other matters can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001, and in its periodic reports on Forms 10-Q and 8-K (if any). ------------------------------------------------------------ Denna information skickades av Waymaker http://www.waymaker.se Följande filer finns att ladda ned: http://www.waymaker.net/bitonline/2003/03/25/20030325BIT00660/wkr0001.doc http://www.waymaker.net/bitonline/2003/03/25/20030325BIT00660/wkr0002.pdf